中西醫(yī)結(jié)合治療原發(fā)性肝癌78例臨床療效和預(yù)后相關(guān)因素分析及其實(shí)驗(yàn)研究
[Abstract]:Objective: to observe the clinical effect of integrated traditional Chinese and western medicine in the treatment of primary liver cancer, to analyze the influence of various factors on the prognosis, and to explore the effect of Shenmai, elemene and compound Sophora flavescens injection on the factors related to the metastasis of hepatocellular carcinoma cells in vitro. Methods: the inpatients and some outpatients with complete data from January 2000 to February 2004 in the affiliated Hospital of Shandong University of traditional Chinese Medicine and Linyi City Hospital of traditional Chinese Medicine of Shandong Province were statistically analyzed. MTT assay was used to observe the killing effect of three kinds of traditional Chinese medicine injection on hepatoma cell line BEL-7402 in vitro. Flow cytometry was used to detect the expression of metastasis related factors (CD44V6 and nm23). Results: there was no significant difference in the survival time of patients with primary liver cancer between radiotherapy and chemotherapy group and conservative treatment group, liver function grade, portal vein thrombus formation, liver function grade, portal vein thrombosis formation, liver function grade, portal vein thrombosis formation, liver function grade, portal vein tumor thrombus formation, Clinical staging, AFP and cirrhosis had different influence on survival rate and evaluation of prognosis. Three kinds of traditional Chinese medicine injection all had different degree of tumor inhibition in vitro, and elemene had the strongest effect in vitro. It also inhibited the expression of CD44v6 and promoted the expression of nm23, and the difference was significant among the three groups. Conclusion: integrated traditional Chinese and western medicine is an effective treatment for primary liver cancer. Chinese medicine can play a comprehensive antitumor effect through direct tumor inhibition and metastasis.
【學(xué)位授予單位】:山東中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2005
【分類號(hào)】:R735.7
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 楊新中,李金彩,鄒銀水,張其軍,譚曉云;對(duì)中醫(yī)腫瘤病因病機(jī)與治療的思考[J];中國醫(yī)藥學(xué)報(bào);1999年06期
2 丁國善,徐冠南,付志仁,李先興;原發(fā)性肝癌對(duì)化療藥物敏感性的研究[J];肝膽胰外科雜志;1999年04期
3 楊新中;中醫(yī)藥防治腫瘤轉(zhuǎn)移的思路[J];湖北中醫(yī)雜志;2002年08期
4 葉紅軍,太京華,姜英,孫述臣,肖紅;原發(fā)性肝癌患者的干擾素、細(xì)胞毒性因子和腫瘤壞死因子的觀察[J];臨床肝膽病雜志;1997年02期
5 牛紅梅,劉嘉湘;中醫(yī)藥抗癌轉(zhuǎn)移的機(jī)理研究[J];遼寧中醫(yī)雜志;2002年04期
6 閆洪飛;中醫(yī)藥防治腫瘤轉(zhuǎn)移的探討[J];上海中醫(yī)藥大學(xué)學(xué)報(bào);2003年04期
7 劉潔,楊世杰,楊旭,陳正,李景洛;蠶蛹蟲草的抗腫瘤及激素樣作用[J];中國中藥雜志;1997年02期
8 王國民,宋美芳,徐懷玉,費(fèi)苛,沈維敏,李南麟;肝癌動(dòng)脈栓塞化療配合全肝移動(dòng)條野放療——60例前瞻性隨機(jī)分組[J];中華放射腫瘤學(xué)雜志;1992年03期
9 李佩文;中藥預(yù)防腫瘤轉(zhuǎn)移的臨床及基礎(chǔ)研究[J];中國腫瘤;1999年01期
10 林洪生,李樹奇,樸炳奎,李攻戍,裴迎霞,祁鑫;三參沖劑對(duì)肺癌轉(zhuǎn)移中內(nèi)皮細(xì)胞及粘附因子的影響[J];中國腫瘤;1999年12期
,本文編號(hào):2280067
本文鏈接:http://sikaile.net/yixuelunwen/zhxiyjh/2280067.html